A disease or disorder is defined as ‘rare’ in Europe when it affects less than 1 in 2,000 individuals.
There are more than 6,000 rare diseases, 80% of which are of genetic origin and are often chronic and very serious; they not only affect the person diagnosed with the disease, but also have an impact on families, friends, caregivers and society as a whole.
Among the many existing rare diseases, some are successfully treated through special nutritional management: PIAM was a pioneer in Italy in this field, making available products for the dietary management of Phenylketonuria, a rare metabolic disease that affects about 1 in 10,000 newborns.
PIAM was also one of the first companies to make some generic drugs derived from orphan drugs available in Italy, offering treatments that are often characterised by innovative formulations and affordable costs for the national health system.
Always committed to the nutritional management of Rare Diseases thanks to its MEDIFOOD division, PIAM confirms its commitment in this sector by including 3 Orphan Drugs in its portfolio in the biennium 2019-2020.
For further information